DrugDashboards

semaglutide

semaglutide · SEMAGLUTIDE 2 mg/mL · Injection, Solution · Novo Nordisk Production Belgium SA

NDC 43835-0030-03 · 1440 CONTAINER in 1 BOX / 1 SYRINGE, GLASS in 1 CONTAINER / .5 mL in 1 SYRINGE, GLASS · DRUG FOR FURTHER PROCESSING · View full market →

Bulk ingredient — not a finished product

This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.

Medicare Part D

This is a bulk ingredient, not a dispensable product — it is a raw material sold to manufacturers and compounders, so no plan prices it.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for semaglutide (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $1,276.18 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
—
TE code
—
Approval date
—
Patents / exclusivity
—

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of semaglutide (Injection, Solution)

LabelerStrengthFirst seenLast seen
A-S Medication SolutionsSEMAGLUTIDE 2.68 mg/mLJul 15, 2026Sep 2, 2026
A-S Medication SolutionsSEMAGLUTIDE 1.34 mg/mLJul 15, 2026Sep 2, 2026
A-S Medication SolutionsSEMAGLUTIDE .25 mg/.5mLJul 15, 2026Sep 2, 2026
Catalent Indiana, LLCSEMAGLUTIDE 1.7 mg/.75mLJul 15, 2026Sep 2, 2026
Catalent Indiana, LLCSEMAGLUTIDE 2.4 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE 2.4 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE .68 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE 2.68 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE .5 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE 1.7 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE .25 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE 1 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE 7.2 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE .25 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE .5 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE .68 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE 1 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE 1.34 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE 1.7 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE 2.4 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE 2.68 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 1 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 1.7 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 2.27 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE .5 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 3.2 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 2.4 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 1 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE .5 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 2 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 2 mg/mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCSEMAGLUTIDE 1.7 mg/.75mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCSEMAGLUTIDE 1 mg/.5mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCSEMAGLUTIDE .25 mg/.5mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCSEMAGLUTIDE 2.4 mg/.75mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCSEMAGLUTIDE .5 mg/.5mLJul 15, 2026Sep 2, 2026
A-S Medication SolutionsSEMAGLUTIDE .68 mg/mLJul 31, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "semaglutide — NDC 43835-0030-03," retrieved September 3, 2026, https://drugdashboards.com/drug/43835003003.

Free to cite with attribution — see how the data is put together.